





































Successful treatment of anti-NMDA receptor
encephalitis with early teratoma removal
and plasmapheresis
A case report
Monica Gomes Ferreira, MDa,b,
∗
, Victoria Lapresa Alcalde, MDa,b, María Helena García Sánchez, MD, PhDa,
Lourdes Hernández Hernández, MD, PhDa,b, María José Doyague Sánchez, MD, PhDa,b
Abstract
Rationale: This report describes a Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and
plasmapheresis.
Patient Concerns: We present a 31-year-old Caucasian nulliparous patient who was admitted as an emergency with general
illness status accompanied by holocranial cephalalgia and fever.
Diagnoses: The previous symptoms were followed by disorientation, persecutory delusion, incoherent language, and tonic-clonic
seizure.
Interventions: The patient was admitted in the intensive care unit (ICU) with Glasgow score 7.
Outcomes:Most of complementary exams (brain CT, brain MRI, blood analysis, PCR for virus on CSF) were normal except CSF
leucocytosis and hyperproteinorrhachia. An abdominopelvic ultrasound revealed a 5-cm solid-cystic tumor in the left adnexal region,
suggestive of teratoma. At that stage, the possibility of autoimmune encephalitis was considered, and confirmed later.
Lessons: This disease can only be successfully treated with fast surgical intervention and an early implementation of
immunosuppressive therapies. The optimal timing of initiation and duration of therapeutic plasma exchange necessary to achieve
good outcomes in patients with NMDAR remains unknown. This case report intends to increase awareness about the importance of
early surgical treatment and early implementation of this potentially life-saving therapy and of continuing the treatment until complete
remission of symptoms.
Abbreviations: Anti-NMDAR = anti-N-methyl-D-aspartate receptor, CSF= cerebrospinal fluid, HSE = herpes simplex
encephalitis, IVIg = intravenous immunoglobulins, TPE = therapeutic plasma exchange, PCR = polymerase chain reaction, CT =
computed tomography, MRI =magnetic resonance imaging, EEG = electroencephalograms, mRS =modified Rankin scale, CNS =
central nervous system.
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1. Introduction
Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis is
an autoimmune disorder with a wide spectrum of neuropsychi-
atric symptoms with a progressive clinical course and the
possibility of effective management, which was first described in
2005 by Vitaliani et al.[1]
A positive serum or CSF sample screening for antibodies to
the NMDAR subunit remains the gold standard in the
diagnosis and must be performed in all patients with an acute
onset of psychiatric symptoms with atypical features or unusual
movements.
The triggers of the disorder include viral infections, tumors,
and other unknown factors. Herpes simplex encephalitis (HSE)
plays a vital role in triggering the synthesis of anti-NMDAR
antibodies.[2] In young adult women, encephalitis is frequently
accompanied with ovarian teratomas,[3,4] while in men and
children the presence of a tumor is uncommon.[5]
Elimination of the ovarian tumor and early immunotherapy
frequently improves the outcome with complete recovery or only
a residual neurological deficit.[6–8]
There is still an important lack of data regarding the optimal
treatment of the disease, predominantly since the type of
immunotherapy that is most effective in controlling the
symptoms of the disease remains a matter of debate. Numerous
patients, particularly those with a severe form of the disease, do
not respond to first-line immunotherapy [steroids or intravenous
immunoglobulins (IVIg)] and may require therapeutic plasma
exchange (TPE).
We report a case of an ovarian mature cystic teratoma in a
young woman which was associated with clinical anti-NMDAR
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encephalitis and the successful therapeutic management applied
by a multidisciplinary team.
2. Case report
The patient is a 31-year-old Caucasian nulliparous woman who
was admitted as an emergency on March 23, 2017 with general
malaise accompanied by holocranial cephalalgia and bilateral
otalgia of 3 days of evolution. The only relevant element in her
history is the presence of migraines without aura. The general
emergencies unit diagnosed her with temporomandibular joint
dysfunction and she returned on the same day with disorienta-
tion, persecutory delusion, and incoherent language. After an
assessment by the Service of Psychiatry, she was diagnosed with
anxiety syndrome secondary to a stressful family situation. On
the next day, she was transferred by the emergency services with
convulsive tonic-clonic seizure which was controlled with
intranasal midazolam, and she was assessed by the Service of
Neurology. She showed intermittently incoherent language and
altered behavior. During anamnesis, she claims that “there are
cameras recording us” or “they want to hurt us.” During the
observation period in the emergency department, she presented
an episode of fever with a temperature of 38.3°C. The blood
results were normal, and the CSF showed 75leukocytes/mm3
(mononuclear) and hyperproteinorrhachia at 88mg/dL, with
clear fluid. The computed tomography (CT) scan did not reveal
significant alterations. The patient was initially diagnosed with
lymphocytic encephalitis and prescribed an antibiotic treatment
against Gram, Gram+, herpesvirus, and tuberculosis (ceftriax-
one, ampicillin, vancomycin, rifater and aciclovir), and antisei-
zure treatment with levetiracetam.
On March 25, the patient was admitted in the intensive care
unit (ICU) with Glasgow score 7 and signs of unrest, language
without response to pain and apraxia of lid opening. She
presented with neck and upper limb dystonia, oculomasticatory
myorhythmia, and involuntary movements of the lower limbs.
During admission, the condition of the patient worsened, with no
language, and she presented with progressive rigidity of the back
of the neck which spread to the entire body, including the
mandible, with sialorrhea. Sedation was applied, followed by
orotracheal intubation and mechanical ventilation. A more
exhaustive study was performed with a complete analysis
(complete blood count, biochemical analysis, coagulation, renal
function, hepatic function, electrolyte levels, polymerase chain
reaction [PCR], glucose, urine analysis, and urine sediment) which
revealed normal values except for PCR, which was 12.2 onMarch
27 (levels were normal on admission). Brain CT and magnetic
resonance imaging (MRI) were performed, without pathological
findings (Fig. 1), and several lumbar punctures that showed CSF
with leukocytes 187/mm3 onMarch 27 and proteins 111.5mg/dL.
On March 28 results for antibodies against neuronal nuclear
antigens (anti-Hu, -Yo, -Ri, -CV2, -PMA2, -amphiphysin,
-recoverin, -SOX1, -titin, -Zic4, -GAD65, and -Tr) were negative.
PCRwas performed for enterovirus, herpesvirus, andMycobacte-
rium tuberculosis, which were negative in CSF. At that stage, the
possibility of autoimmune encephalitis was considered, and a CSF
sample was submitted to an external laboratory for the study of
anti-NMDA glutamate receptor antibodies.
After showing immunoglobulin A levels within normal values,
the patient was treated with immunoglobulins, 0.4g/kg/day for 2
days, followed by 1g/day methylprednisolone for 5 days. Given
the lack of improvement after the second dose of immunoglo-
bulins, rituximab was administered at 375mg/m2/week.
OnMarch 31, 2017, an abdominopelvic ultrasound revealed a
moderate amount of free fluid in the pelvis, and a 5-cm solid-
cystic tumor in the left adnexal region, suggestive of teratoma
(Fig. 2). Given the suspicion of autoimmune encephalitis
secondary to teratoma, an emergency surgical excision was
decided by the Service of Gynecology. A laparoscopic left
salpingo-oophorectomy was performed and it showed an image
compatible with teratoma (Fig. 3)—which was confirmed in the
postoperative analysis by pathological anatomy: “Mature cystic
teratoma.” Multiple lavages of the abdominal cavity were
performed to prevent—according to the literature—a chemical
peritonitis caused by a potential spillage of the fluid of the
sebaceous cyst.
Similarly, onApril 4 our suspicionswere confirmedwithpositive
results in CSF for oligoclonal bands and anti-NMDA glutamate
receptor antibodies, with titre 1:64 (negative in blood). Anti-
AMPA 1 and 2 glutamate receptor, anti-LGI1, anti-GABAB1/B2
receptor and anti-VGKC antibodies were negative.
Figure 1. MRI—nonpathological findings. MRI=magnetic resonance imaging.
Figure 2. US—imagecompatiblewith5cmleftovarianteratoma.US=Ultrasound.
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In the immediate postoperative period, the patient showed a
slight improvement of her general symptoms. Afterward, she
presented with fever of infectious origin, a maintained coloniza-
tion of enterococci in blood and of multi-resistant Pseudomonas
aeruginosa in bronchial aspirate. Consequently, the treatment
with monoclonal antibodies was interrupted and plasmapheresis
cycles were initiated (3 cycles with 5 sessions per cycle in total),
with alternate-day high doses of steroids. A slight improvement in
the myoclonus was observed after each session. The jejunal
biopsy was negative for Whipple’s disease on April 10. Repeated
electroencephalograms (EEG) were performed, and they revealed
generalized slowing with unspecific characteristics and without
evidence of paroxysmal activity. Since May 11, a slight
improvement was observed, with a decrease in myoclonic
activity, which made it possible to reduce the sedation doses.
On June 27, after several days without fever and without any
evidenceof infection, treatmentwith rituximabwas initiatedagain.
In total, 4 doses were administered without relapse of infection.
On July 12, during one of the periods in which sedation was
withdrawn and with almost no antiseizure treatment, the EEG
(Fig. 4) showed clear epileptic activity and the antiseizure
treatment was increased.
Figure 3. Laparoscopic surgery—image compatible with ovarian teratoma.
Figure 4. Epileptic activity in EEG. EEG=electroencephalograms.
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Given the profuse sialorrhea of the patient, which even
interfered with her fluid balance, botulinum toxin was applied on
July 22. Sialorrhea disappeared without signs of mouth dryness
until discharge. On September 7, the tracheotomy cannula was
removed.
The CSF and blood parameters during this period are
presented in Table 1.
After 5 months in the ICU and several weeks in the Service of
Neurology, the patient was discharged on September 29, 2017
with Glasgow score 15 and modified Rankin Scale (mRS) 3. She
was capable of maintaining a conversation with some fluency and
presented with slight dysarthria and ambulation with assistance.
The anti-NMDA antibodies started to decrease 5 months after
surgery. The patient is currently under antiepileptic and
rehabilitation treatment, and she is monitored by the Service
of Neurology.
Due to there is no concern that a patient’s anonymity cannot be
maintained in written text or with use of photographs we
consider that the ethical approval was waived or not necessary.
However, the patient has provided informed consent for
publication of the case.
A timeline of the events is present in Figure 5.
3. Discussion
Encephalitis is an acute or chronic inflammatory disease of the
central nervous system (CNS) where the presence of the neuronal
surface antibodies can be demonstrated.[6] The present clinical
Figure 5. Timeline of events.
Table 1
Follow-up of cerebrospinal fluid (CSF) and blood parameters.
25/03 27/03 07/04 02/06 30/08 Normal range
Anti-NMDAr antibodies
∗
1:64 1:64 1:16 <1:10
Leukocytes (leucocytes/mm3) 75 187 35 3 1 <4
Proteins, mg/dL 88 98 31 112 66 1.00–40.00
Glucose, mg/dL 73 63 72 54 63 40-80
Macroscopic appearance Clear Clear Clear Clear
Oligoclonal bands (CSF) Positive Positive (weak)
Ig G serum blood test, mg/dL 873 4560 2430 751–1560
Serum oligoclonal bands Negative
Anti- NMDAr= anti-N-methyl-D-aspartate receptor, CSF= cerebrospinal fluid, Ig G= immunoglobulin G.
∗
Significant levels of anti-NMDA antibodies are considered from title 1:2.
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case described a progression of anti-NMDAR encephalitis. This
relatively unusual disorder has a typical chronological presenta-
tion: sudden onset with prodromal, fever-like symptoms,
followed by a psychiatric disorder, decreased level of conscious-
ness with focal and clonic seizures, dyskinesias, and autonomic
instability.[7] In our clinical case, all of the cited symptoms were
observed, so the clinical course of the anti-NMDAR encephalitis
was typical. Furthermore, the patient was a young woman, which
is also a common feature of this type of autoimmunological
encephalitis. The female patient population represents around
80% of reported cases.[8] Additionally, the coexistence of an
ovarian tumor, a teratoma in this case, is also typical for anti-
NMDAR encephalitis.
When anti-NMDAR is suspected the diagnostic tests contain
detectionofNMDARautoantibodies inCSFand/or in the serumas
the fundamental part of diagnosis, predominantly because other
laboratory tests and imaging studies are not relevant.[9] According
to some authors, CSF antibody testing is highly sensitive and
specific for anti-NMDAR encephalitis and false positive and
negative results may occur when testing only serum.[10]
There is currently some discussion as to whether serum or CSF
must be tested for in the presence of anti-NMDAR antibodies. In
the present case, high levels of anti-NMDAR antibodies were
detected in the CSF, but not in the plasma. The association
between the prodromal flu-like symptoms and the antibodies
against NMDAR is also a material of debate. Some authors
emphasize the connection between a viral infection and injury of
the blood–brain barrier, which facilitates transmission of
NMDAR autoantibodies to the CNS.[11]
An EEG may be important in distinguishing between primary
psychiatric disorder and encephalitis, since a vast majority of
patients with anti-NMDAR encephalitis exhibit nonspecific
slowing at a certain stage during the illness.
Treatment for anti-NMDAR encephalitis remains challenging,
due to the fact that no complete guidelines have been published to
date.
The wide majority of authors agree that treatment must target
both the cause and the clinical consequences of the encephalitis.
Anti-NMDAR encephalitis treatment is more effective in patients
who have a primary tumor removed and there are cases in which
ovarian teratomas were discovered years after the initial onset of
symptoms, mainly in patients with a slow recovery.[12] Some
authors believe in early oophorectomy even in cases when the
presence of an ovarian tumor cannot be established in imaging
studies. In a case described by Peery et al[12] postoperative biopsy
discovered an occult teratoma, and the tumorectomy resulted in
an improvement of the symptoms. In most cases, immunotherapy
is the first-line treatment and includes corticosteroids, IVIg and
TPE, unaccompanied or in combination.[13] The second-line
treatment includes rituximab and cyclophosphamide, and is used
in patients who show a late diagnosis or did not have a primary
malignancy.[14]
In the present case, the patient was firstly treated with
corticosteroids (methylprednisolone), IVIg and rituximab. Nev-
ertheless, she started with repeated infections, so rituximab had
to be stopped. This first-line immunosuppressive treatment failed
to produce any improvement of the patient’s clinical condition.
She only improved following the TPE, although clinical
improvement of anti-NMDAR encephalitis is not always
achieved with TPE.[15,16] According to the guidelines published
by the American Society for Apheresis, the use of TPE must be
considered as a third-line treatment in paraneoplastic neurologi-
cal syndromes (grade 2C).[17] Regarding the role of plasmaphe-
resis, we still have several debates and conflicting data in the
literature. According to Dalmau et al[5] the use of plasmapheresis
should not be routinely. On the other hand, there are recent data
supporting the use of plasmapheresis to improve the patient
clinical status.[18,19] DeSena et al[20] compare the use of
plasmapheresis alone versus before intravenous corticoids in
the treatment of anti-NMDAR receptor encephalitis, with better
results in the last case.
This case report has some strengths and some limitations.
Regarding the limitations, it is not based on systematic studies so,
it may not be generalizable. However, this case report may help
the medical identification of this rare disease and therefore is an
important educational article.
4. Conclusion
NMDAR encephalitis mainly affects young women with ovarian
teratomas and is a potentially lethal but reversible disorder with a
good clinical outcome if diagnosed and treated promptly. The
gold standard for diagnosing anti-NMDAR encephalitis is the
detection of IgG antibodies against the GluN1 subunit of NMDA
receptors in either the CSF or plasma; however, other diagnostic
measures, including EEG or MRI may also assist clinicians in
obtaining the diagnosis. The early detection of tumor, its surgical
removal, and early immunotherapy make it possible to shorten
the progression of disease, improve the survival rates, and limit
the negative long-term consequences for the patients. So far TPE
must similarly be considered in the clinician’s armamentarium,
mainly in cases where initial treatment has failed. In the current
case, a long-term follow-up examination revealed a good clinical
outcome, without any major neurological or psychiatric
complications following the anti-NMDAR encephalitis. A
multidisciplinary team, including gynecologist, psychiatrists,
neurologists and intensivists, must be involved in the process
of recognition and management of the disease. Available data
remain unclear and therefore there is an urgent need for good
quality clinical trials.
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